Crystal Pharmaceutical Suzhou Co Ltd

General

Total Cases16

Active Cases3

Patents33

CourtsD. Delaware N.D. California D. Nevada

TypeOperating Company

Elite Ratings

--

crystalpharmatech.com.cn

crystal-pharmatech

crystal-pharmatech

Ratings

Experience

Grade

Trend

DCT

--

--

--

PTAB

L2

D

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
11/08/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	NOTICE OF SERVICE of Defendants MSN Pharmaceuticals Inc., MSN Laboratories Private Limited, and MSN Life Sciences Private Limiteds Notice Pursuant to 35 U.S.C. § 282 filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc..(Weinblatt, Richard) (Entered: 11/08/2024)
11/08/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	MEMORANDUM ORDER: The Daubert Motions (D.I. 1555 , 1559 ) are DENIED without prejudice to any specific objections at trial. (See Memorandum Order for further details). Signed by Judge Richard G. Andrews on 11/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:22-cv-01395-RGA (aas) (Entered: 11/08/2024)
11/08/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	REDACTED VERSION of [341] Letter, by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) Modified on 11/8/2024 (nms). (Entered: 11/08/2024)
11/07/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	REDACTED VERSION of [349] Declaration, by Gerbera Therapeutics Inc., MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc., Nanjing Noratech Pharmaceutical Co., Limited. (Gattuso, Dominick) Modified on 11/7/2024 (nms). (Entered: 11/07/2024)
11/07/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	SECOND REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [341] . (nms) (Entered: 11/07/2024)
11/07/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	SECOND REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [349] . (nms) (Entered: 11/07/2024)
11/04/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	ORAL ORDER: The redacted filings (D.I. [367] , [369] ) are REJECTED because parts of them are redacted in their entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. Revised redacted filings are DUE within five business days. Ordered by Judge Richard G. Andrews on 11/4/2024. (nms) (Entered: 11/04/2024) ORAL ORDER: The redacted filings (D.I. [367] , [369] ) are REJECTED because parts of them are redacted in their entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. Revised redacted filings are DUE within five business days. Ordered by Judge Richard G. Andrews on 11/4/2024. (nms) (Entered: 11/04/2024)
11/04/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [341] . (nms) (Entered: 11/04/2024)
11/04/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	REDACTION NOTICE: In accordance with section G of the Administrative Procedures Governing Filing and Service by Electronic Means, redacted versions of sealed documents shall be filed electronically within 7 days of the filing of the sealed document. The records of this case do not reflect the filing of a redacted version of DI # [349] (nms) (Entered: 11/04/2024)
11/03/24	Novartis Pharmaceuticals Corp v. MSN Pharmaceuticals Inc 1:22-CV-01395 ( D. DE )	REDACTED VERSION of [346] Declaration, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/4/2024 (nms). (Entered: 11/03/2024)